All articles tagged with #cbd
Millions use cannabis to aid sleep, but research shows a split: THC can help some fall asleep faster, yet it may disrupt REM sleep and overall sleep quality, especially with chronic use. Tolerance grows, REM rebound can occur after stopping, and the long-term effects on memory and emotional regulation remain uncertain.
A large, longitudinal study of 11,036 U.S. youths aged about 9–10 to 16–17 found that cannabis use during adolescence is linked to slower development across memory, attention, and processing speed, with THC exposure driving most of the effects and CBD exposure showing relatively normal scores. While causality can’t be proven, researchers controlled for family background, mental health, and other substances, suggesting that delaying cannabis use may help protect the developing brain. The findings come from the ABCD study and were published in Neuropsychopharmacology, with even small cognitive differences potentially affecting learning, standardized testing, and daily functioning.
Federal health officials asked a court to dismiss a lawsuit by anti-cannabis groups led by SAM and a Medicare patient challenging CMS’s voluntary hemp-derived products coverage under Medicare, arguing the plaintiffs lack Article III standing and that the BEI component is not a new entitlement. The policy allows hemp-derived products (CBD) with up to 0.3% delta-9 THC and up to 3 mg total THC per serving, and is funded by providers up to a $500 annual cap per beneficiary. Plaintiffs contend the program diverts resources and harms their goals, but the government says there is no injury and no rulemaking required for this voluntary model. The case may seek to add MMJ as plaintiffs, a TRO was previously denied, and the matter continues to hinge on federal hemp vs. marijuana policy.
Israeli researchers found that non-psychoactive cannabis compounds CBD and CBG can reverse liver damage in obese mice with MASLD by reprogramming liver energy use, boosting phosphocreatine reserves and lysosomal activity, and improving insulin resistance and lipid profiles. The treated mice showed reduced fat accumulation and inflammation without dietary changes, suggesting a new metabolic pathway to target in MASLD. However, these results are preclinical, and human relevance requires careful dosing considerations and clinical trials, as consumer CBD/CBG products vary in purity and concentration.
In obese mice fed a high-fat diet, CBD and CBG improved liver function, reduced hepatic fat, lowered blood lipids, and enhanced insulin sensitivity, with CBG generally more effective. The benefits appear to arise from reprogramming hepatic energy and lysosomal pathways rather than activating classic cannabinoid receptors, and were achieved via abdominal injections. While promising for MASLD, human relevance remains to be tested and CBD product quality is variable.
New research shows non-psychoactive cannabis compounds CBD and CBG can significantly reduce liver fat and cholesterol, improve liver energy metabolism, and restore cellular cleanup (lysosomal) function, offering a plant-based approach to MASLD, the world’s most common chronic liver disease. The study also found both compounds normalize blood sugar, with CBG showing stronger effects on fat reduction and insulin sensitivity; further research is needed to translate these findings into treatments.
A scientific review suggests that CBD, a non-intoxicating compound in marijuana, shows significant potential as an anti-tumor agent across various cancers, including aggressive types like glioblastoma, by disrupting multiple cancer pathways. However, challenges such as poor absorption and delivery methods remain, and further clinical research is needed to confirm its efficacy in patients.
A review led by OHSU found that some cannabis products, particularly those containing THC, can slightly reduce chronic pain, similar to traditional painkillers like ibuprofen, but the effect is small and may come with side effects. CBD alone showed little to no impact on pain, and the findings suggest caution in using cannabis for pain management, emphasizing the need for further research and personalized medical advice.
In North Carolina, marijuana remains illegal, but hemp products with less than 0.3% THC are legal, though a new federal law set to take effect in 2026 may ban these products due to increased THC limits, threatening the state's multi-billion-dollar hemp industry and raising public safety concerns. The debate involves federal and state regulations, industry impacts, and public health considerations.
A review of clinical trials indicates that high-THC cannabis products may offer modest short-term relief for chronic pain, especially nerve pain, but they also increase the risk of side effects. CBD-only products do not appear to provide significant pain relief. The findings highlight the need for more research on long-term effects and safety.
President Donald Trump signed an executive order to expand access to marijuana and CBD, citing their medical benefits, as part of a broader move to ease restrictions despite not decriminalizing the substances.
President Trump signed an executive order to reclassify cannabis from Schedule I to Schedule III, aiming to expand research and access, while maintaining federal illegality; the move has received mixed reactions from lawmakers and the public.
Laboratory studies suggest that a combination of cannabis-derived compounds THC and CBD can inhibit the growth and spread of ovarian cancer cells with minimal effects on healthy cells, offering potential for new, less toxic treatments, though further research is needed to confirm efficacy and safety in vivo.
President Trump is expected to sign an executive order reclassifying cannabis as a Schedule III drug, which could expand access to CBD products, include Medicare coverage for seniors, and significantly impact the cannabis industry, research, and investments, despite ongoing scientific and regulatory debates.
A last-minute provision in a federal spending bill aiming to restrict hemp-derived products like CBD and THC has caused disquiet among Republicans, especially in hemp-producing Kentucky, threatening the bill's passage and the end of the government shutdown. The provision, which bans products with more than 0.4 mg of THC per container, is opposed by some lawmakers and industry leaders who argue it could lead to an unregulated market and harm consumers. The bill is expected to pass with some opposition, and advocates hope to replace the ban with more thoughtful regulations.